They describe good effects of high-dose ascorbate in combination with anti-PD1 therapy in a lymphoma mouse model [35], whereas Magri et al. demonstrated that the tumor volume in colon, pancreatic, and breast cancers was significantly reduced by the combined administration of ascorbate with anti-PD1 or anti-CTLA4 in mice [36]. Here, CTLA4 is linked to neoplasm.